Quality → Champions

India’s Pharmaceutical Champions

The companies powering India’s pharmaceutical industry — from Hyderabad labs to FDA-registered plants spanning five continents. Thirty-one companies profiled here, with revenue from annual reports, FDA drug approvals from Drugs@FDA, patent grants from the Indian Patent Office, and manufacturing registrations from the US FDA.

31

Companies Profiled

4,400+

US FDA Drug Approvals

200+

FDA-Registered Plants

150+

Countries Served

Revenue Leaders — FY 2025

The ten largest Indian pharmaceutical companies by annual revenue, from published annual reports.

The Big Three

Sun Pharmaceutical Industries

India’s largest — from a psychiatry niche in Baroda to specialty pharma across 100+ countries

FY 2025 Revenue

Aurobindo Pharma

#1 in US by prescriptions dispensed (per IQVIA) — vertical integration from API to finished dose across 150+ countries

FY 2025 Revenue

The company that broke the AIDS drug cartel — $1/day ARVs changed global health forever

FY 2025 Revenue

IPA Champions

Members of the Indian Pharmaceutical Alliance — the companies that collectively account for the majority of India’s pharmaceutical exports and domestic production.

Dr. Reddy’s Laboratories

The API pioneer — NYSE-listed, built India’s first Paragraph IV patent challenge

$2.99B 394 FDA Approvals 13 FDA Plants 24,800

Zydus Lifesciences

World’s first dual PPAR agonist (Saroglitazar) — from generics to new molecules

$2.77B 481 FDA Approvals 12 FDA Plants 27,000

3rd largest Indian pharma by US prescriptions (per IQVIA) — from tuberculosis to complex generics

$2.7B 308 FDA Approvals 14 FDA Plants 24,000

Among the world’s largest ARV API producers — supplying anti-retrovirals across the developing world

$2.5B 196 FDA Approvals 11 FDA Plants 30,000

From a Bangalore garage to global biosimilars leader — Kiran Mazumdar-Shaw’s four-decade bet

$1.95B 40 FDA Approvals 8 FDA Plants 16,500

Glenmark Pharmaceuticals

The innovation gamble — dermatology, respiratory, oncology across 80+ countries

$1.6B 216 FDA Approvals 7 FDA Plants 15,800

Alkem Laboratories

India’s acute therapy leader — anti-infectives and gastrointestinal care since 1973

$1.6B 164 FDA Approvals 4 FDA Plants 19,000

India’s domestic pharmacy — deepest rural distribution, IPO’d 2023

$1.5B 65 FDA Approvals 3 FDA Plants 28,000

Torrent Pharmaceuticals

Leading Indian pharma in Brazil and Germany — the branded generics specialist

$1.38B 135 FDA Approvals 5 FDA Plants 17,300

Macleods Pharmaceuticals

Medicine for the world — essential anti-TB and antimalarials to Africa and Asia

$1.2B 177 FDA Approvals 4 FDA Plants 15,000

Emcure Pharmaceuticals

Science-led, patient-first — women’s health and complex formulations, IPO’d July 2024

$948M 14 FDA Approvals 4 FDA Plants

Home of Dolo-650 — the paracetamol brand that became a household name during COVID

$900M 123 FDA Approvals 5 FDA Plants 14,000

IPCA Laboratories

Global antimalarial leader — 75 years of chemistry, from APIs to finished formulations

$870M 33 FDA Approvals 7 FDA Plants 17,000

The volume champion — large-scale manufacturing of the world’s most-used molecules

$648M 71 FDA Approvals 5 FDA Plants 4,066

The emerging-markets specialist — branded generics in Africa, Asia, and beyond

$560M 79 FDA Approvals 2 FDA Plants 9,600

The first-to-file strategist — Paragraph IV patent challenges, oncology access pioneer

$534M 91 FDA Approvals 4 FDA Plants

Wockhardt Limited

The antibiotic pioneer — 6 QIDP-designated novel antibiotics against superbugs

$369M 82 FDA Approvals 2 FDA Plants

Indoco Remedies

Seven decades of formulation expertise — the quiet achiever in Indian pharma

$221M 4 FDA Approvals 7 FDA Plants 6,000

FDA Approvals Leaders

Approved drug applications (ANDA + NDA) at the US Food and Drug Administration. ANDAs are generic drug approvals; NDAs are new drug approvals. Data from Drugs@FDA.

CDMO & Research Services

The contract development, manufacturing, and research organisations that power global drug discovery and production from Indian soil.

Divi’s Laboratories

India’s premier API manufacturer — backward integration and chemistry at extraordinary scale

$1.1B 7 FDA Approvals 2 FDA Plants 16,000

The ARV engine — from anti-retroviral APIs to oncology CDMO and biotech

$667M 35 FDA Approvals 7 FDA Plants 7,000

The difficult-to-manufacture specialist — soft gels, controlled substances, sterile injectables

$547M 233 FDA Approvals 3 FDA Plants 3,690

Jubilant Ingrevia

Among the world’s largest pyridine producers — specialty chemicals to integrated CDMO

$501M 88 Indian Patents 2 FDA Plants 2,300

Syngene International

The research partner — 14 of the top 20 global pharma companies as clients

$430M 4 FDA Plants 8,235

Where pharma meets agriculture — dual CDMO expertise across crop protection and pharmaceuticals

$224M 3 Indian Patents 2 FDA Plants 2,400

Aragen Life Sciences

Discovery to manufacturing — end-to-end CRDMO serving 6 of the top 10 global pharma

$222M 4 FDA Plants 4,500

Sai Life Sciences

End-to-end CRDMO — IPO’d December 2024, serving 18 of top 25 global pharma

$203M 3 FDA Plants 3,401

Neuland Laboratories

Four decades of chemistry — from generic APIs to peptide synthesis and custom manufacturing

$180M 2 Indian Patents 3 FDA Plants 1,794

Suven Pharmaceuticals

The CDMO specialist — NCE intermediates for global innovators, Advent-backed

$132M 61 Indian Patents 1,200

The Indian Pharmaceutical Alliance represents India’s leading research-based pharmaceutical companies. Together, IPA members represent a significant share of India’s pharmaceutical exports and domestic production.

About the Indian Pharmaceutical Alliance →